Document:

Exhibit 10.29

 

EXECUTION COPY

 

AMENDMENT NO. 1

TO

TRANSACTION
AGREEMENT

 

THIS
AMENDMENT NO. 1 TO TRANSACTION AGREEMENT (this “Amendment”), dated as of
January 16, 2006, between BOSTON SCIENTIFIC CORPORATION, a Delaware
corporation (“Boston Scientific”), and ABBOTT LABORATORIES, an Illinois
corporation (“Abbott”).

 

WHEREAS,
Boston Scientific and Abbott are parties to that certain Transaction Agreement
dated as of January 8, 2006 pursuant to which Abbott agreed to acquire
certain assets and businesses and assume certain liabilities of Guidant
contingent upon Boston Scientific’s acquisition of Guidant (the “Agreement”);

 

WHEREAS,
Boston Scientific has advised Abbott that it desires to increase the amount of
the merger consideration it is offering to pay Guidant shareholders in its
proposed acquisition of Guidant; and

 

WHEREAS,
Boston Scientific and Abbott desire to amend the Agreement as provided in this
Amendment in accordance with Section 11.07 of the Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing and the promises and mutual
agreements contained in this Amendment, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, and
intending to be legally bound, the parties hereto agree as follows:

 

SECTION 1.  Amendments to the Agreement. (a) The
parenthetical reference (the “Merger Agreement”) is hereby deleted from the
first recital.

 

(b)                       The phrase “entry into the Merger Agreement”
in the third recital is hereby amended and restated to read “entry into the
Agreement and Plan of Merger (as such agreement is actually entered into by
such parties, and as it may be amended from time to time, the “Merger Agreement”)”

 

(c)                        The first sentence of Section 2.03(a) of
the Agreement is hereby amended and restated to read as follows:

 

“Abbott
shall pay, or cause the applicable Purchaser to pay, an aggregate purchase
price for the Assets equal to the sum of: (i) an amount in cash equal to (A) $3,800,000,000
(the “Base Purchase Price”) plus (B) an amount determined in
accordance with the provisions of Section 2.03(c) (the “Incremental
Purchase Price”), which Incremental Purchase Price shall not exceed
$300,000,000 (the sum of the amounts described in clauses (A) and (B),

 

 

the
“Initial Purchase Price”), (ii) the Milestone Payments, and (iii) the
Assumed Liabilities (collectively, the “Purchase Price”).”

 

(d)                       The following new Section 2.03(c) shall
be added to the Agreement:

 

“(c)                            The amount, if any, of the Incremental
Purchase Price shall be determined as follows:

 

(i)             if
the Boston Scientific Incremental Value is equal to $1,800,000,000 or more,
then the Incremental Purchase Price shall be $300,000,000; or

 

(ii)          if
the Boston Scientific Incremental Value is less than $1,800,000,000 but greater
than $0, then the Incremental Purchase Price shall be an amount equal to
$300,000,000 multiplied by a fraction, the numerator of which is the Boston
Scientific Incremental Value and the denominator of which is $1,800,000,000.

 

(iii)       “Boston
Scientific Incremental Value” means the product of the number of shares of
Company Common Stock and (on a fully diluted basis) Company Stock Options (each
as defined in the Merger Agreement) outstanding immediately prior to the
Merger, multiplied by the excess of (A) the sum of (i) the Cash Portion
(as defined in the Merger Agreement) plus (ii) the product of the Stock
Portion multiplied by the Parent Average Closing Stock Price (each as defined
in the Merger Agreement) (as adjusted consistently with the proviso in clause (i) of
Section 2.01(c) of the Merger Agreement) plus (iii) the Interest
Portion (as defined in the Merger Agreement) over (B) $72. Boston
Scientific will provide written notice to Abbott of the amount, if any, of
Boston Scientific Incremental Value on the second Business Day prior to the
date of the Closing. The parties agree that under no circumstances will any
other adjustment or modification that Boston Scientific may make in connection
with its offer to acquire Guidant, whether or not such adjustments or
modifications are reflected in the Merger Agreement signed by Boston Scientific
and Guidant, be included in the determination of Boston Scientific Incremental
Value.”

 

(e)                        Section 5.01(b) of the Agreement is
hereby amended and restated to read as follows:

 

“(b)            Boston Scientific has provided to Abbott on January 8
a draft of the Agreement and Plan of Merger proposed to be entered into between
Boston Scientific and Guidant (such proposed draft, the “Proposed Merger
Agreement”). The Merger Agreement, if any, will, insofar as it relates to the
Business, be the same in all material respects, as the Proposed Merger
Agreement.”

 

2

 

(f)                          Clause (ii) of Section 5.02 of the
Agreement is hereby amended by replacing the phrase “contained in the Merger
Agreement” with the phrase “contained in the Proposed Merger Agreement”.

 

(g)                       The first sentence of Section 5.08(k) of
the Agreement is hereby amended by replacing the phrase “for a period of five
years” with the phrase “for a period of eight years”.

 

(h)                       The first sentence of Section 5.10(a) of
the Agreement is hereby amended and restated to read as follows:

 

“At
the Closing, Abbott will lend Boston Scientific an amount equal to (A) $700,000,000
(the “Base Loan Amount”) plus (B) an amount determined in
accordance with the provisions of Section 5.10(c) (the “Incremental
Loan Amount”), on a subordinated basis (relative to any senior indebtedness
of Boston Scientific during the term of the loan) by wire transfer of
immediately available funds to a bank account designated in writing by Boston
Scientific to Purchaser not fewer than three Business Days prior to the date of
Closing.”

 

(i)                           The fourth sentence of Section 5.10(a) of
the Agreement is hereby amended and restated to read as follows:

 

“Interest
shall accrue on the outstanding principal amount of the loan at a per annum
rate of: (A) 5.25% (the “Base Interest Rate”) less (B) the
number of basis points determined in accordance with the provisions of Section 5.10(d) (the
“Interest Rate Decrease”).”

 

(j)                           The following new Section 5.10(c) shall
be added to the Agreement:

 

“(c)                            The amount, if any, of the Incremental Loan
Amount shall be determined as follows:

 

(i)             if
the Boston Scientific Incremental Value is equal to $1,800,000,000 or more,
then the Incremental Loan Amount shall be $200,000,000; or

 

(ii)          if
the Boston Scientific Incremental Value is less than $1,800,000,000 but greater
than $0, then the Incremental Loan Amount shall be an amount equal to
$200,000,000 multiplied by a fraction, the numerator of which is the Boston
Scientific Incremental Value and the denominator of which is $1,800,000,000.”

 

(k)                        The following new Section 5.10(d) shall
be added to the Agreement:

 

“(d)                           The amount, if any, of the Interest Rate Decrease shall be determined
as follows:

 

(i)             if the Boston Scientific Incremental Value is
equal to $1,800,000,000 or more, then the Interest Rate Decrease shall be 125
basis points (such that the interest rate on the loan is 4.0% per annum); or

 

3

 

(ii)          if
the Boston Scientific Incremental Value is less than $1,800,000,000 but greater
than $0, then the Interest Rate Decrease shall be a number of basis points
equal to 125 multiplied by a fraction, the numerator of which is the Boston
Scientific Incremental Value and the denominator of which is $1,800,000,000.”

 

(1)                                  Section 10.02(b)(i) of the
Agreement is hereby amended by replacing the phrase “contained in Section 4.01
of the Merger Agreement” with the phrase “contained in Section 4.01 of the
Proposed Merger Agreement”.

 

SECTION 2.  Effectiveness. This Amendment shall be
effective only with respect to offers to acquire Guidant that are communicated
in writing by Boston Scientific to the Board of Directors of Guidant on or
before January 20, 2006.

 

SECTION 3.  Public Announcement. The provisions
contained in Section 11.03 of the  Agreement are incorporated by reference in this Amendment as though
they were expressly set forth herein.

 

SECTION 4.  Representations and Warranties. (a) Boston
Scientific represents and warrants to Abbott as follows: Boston Scientific is a
corporation duly incorporated, validly existing and in good standing under the
Laws of the State of Delaware and has all necessary corporate power and
authority to enter into, execute and deliver this Amendment. The execution and
delivery of this Amendment by Boston Scientific have been duly authorized by
all requisite corporate action on the part of Boston Scientific. This Amendment
has been duly executed and delivered by Boston Scientific, and, assuming due
authorization, execution and delivery by Abbott, this Amendment is a legal,
valid and binding obligation of Boston Scientific, enforceable against it in
accordance with its terms.

 

(b)                                 Abbott represents and warrants to Boston Scientific
as follows: Abbott is a corporation duly incorporated, validly existing and in
good standing under the Laws of the State of Illinois and has all necessary
corporate power and authority to enter into, execute and deliver this
Amendment. The execution and delivery of this Amendment by Abbott have been
duly authorized by all requisite corporate action on the part of Abbott. This
Amendment has been duly executed and delivered by Abbott, and, assuming due
authorization, execution and delivery by Boston Scientific, this Amendment is a
legal, valid and binding obligation of Abbott enforceable against it in
accordance with its terms.

 

SECTION 5.  Ratification of Agreement. Except as
expressly provided in this Amendment, all of the terms, covenants, and other
provisions of the Agreement are hereby ratified and confirmed and shall
continue to be in full force and effect in accordance with their respective
terms. From and after the date hereof, all references to the Agreement shall
refer to the Agreement as amended by this Amendment. Capitalized terms used but
not defined in this Amendment shall have the meanings assigned to them in the
Agreement.

 

4

 

SECTION 6.  Governing Law. This Amendment shall be
governed by, and construed in accordance with, the laws of the State of New
York. All Actions arising out of or relating to this Amendment shall be heard
and determined exclusively in any New York federal court sitting in the Borough
of Manhattan of The City of New York.

 

SECTION 7.  Counterparts. This Amendment may be
executed and delivered (including by facsimile transmission) in one or more
counterparts, and by the different parties hereto in separate counterparts,
each of which when executed shall be deemed to be an original, but all of which
taken together shall constitute one and the same agreement.

 

* 
*  *  *

 

5

 

IN WITNESS WHEREOF, Boston Scientific and Abbott have caused this Amendment
to be executed as of the date first written above by their respective officers
thereunto duly authorized.

 

	
   

  	
  BOSTON SCIENTIFIC
  CORPORATION

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Lawrence
  C. Best

  	
   

  
	
   

  	
  Name:

  	
  Lawrence C.
  Best

  
	
   

  	
  Title:

  	
  Executive
  Vice President, Chief

  Financial Officer

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  ABBOTT
  LABORATORIES

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Richard
  A. Gonzalez

  	
   

  
	
   

  	
  Name:

  	
  Richard A.
  Gonzalez

  
	
   

  	
  Title:

  	
  President
  and Chief Operating

  Officer, Medical Products

  GroupExhibit 10.30

 

EXECUTION
COPY

 

AMENDMENT NO. 2

TO

TRANSACTION AGREEMENT

 

THIS
AMENDMENT NO. 2 TO TRANSACTION AGREEMENT (this “Amendment”), dated as of
January 16, 2006, between BOSTON SCIENTIFIC CORPORATION, a Delaware
corporation (“Boston Scientific”), and ABBOTT LABORATORIES, an Illinois
corporation (“Abbott”).

 

WHEREAS,
Boston Scientific and Abbott are parties to that certain Transaction Agreement
dated as of January 8, 2006 and amended as of January 16, 2006,
pursuant to which Abbott agreed to acquire certain assets and businesses and
assume certain liabilities of Guidant contingent upon Boston Scientific’s
acquisition of Guidant (the “Agreement”); and

 

WHEREAS,
Boston Scientific and Abbott desire to further amend the Agreement as provided
in this Amendment in accordance with Section 11.07 of the Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing and the promises and mutual
agreements contained in this Amendment, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, and
intending to be legally bound, the parties hereto agree as follows:

 

SECTION 1.  Amendment to the Agreement. The
following new Article VI shall be added to the Agreement, with the
existing Articles VI through XI and Sections within such articles being
renumbered accordingly:

 

ARTICLE VI

 

SHARE PURCHASE

 

SECTION 6.01.  Share
Purchase. (a) At the Closing, Abbott shall purchase from Boston
Scientific, and Boston Scientific shall issue and sell to Abbott, 56,000,000
shares of common stock, par value $0.01 per share, of Boston Scientific (the “Shares”)
at a purchase price of $25.00 per Share, for an aggregate purchase price of
$1,400,000,000 (the “Aggregate Stock Purchase Price”); provided
that if the average of the per share closing prices of Shares on the New York
Stock Exchange during the five consecutive trading days ending (and including)
the date that is three trading days prior to the date of the Closing is less
than $25.00, Abbott shall purchase from Boston Scientific, and Boston
Scientific shall issue and sell to Abbott, the number of Shares that is equal
to the quotient obtained by dividing $1,400,000,000 by such average per share
closing price (the per Share purchase price payable by Abbott or the applicable
Purchaser under this Section 6.01(a) being, the “Stock Purchase
Price”). In no event shall the number of Shares acquired by Abbott pursuant
to this Section 6.01 (a) equal or exceed 5% of the number of

 

 

Shares
outstanding immediately following the consummation of the Merger, and, in such
event, the Aggregate Stock Purchase Price shall be adjusted accordingly.

 

(b)                                 At the Closing, (i) Abbott shall pay the
aggregate Stock Purchase Price by wire transfer of immediately available funds
to a bank account designated in writing by Boston Scientific to Abbott not
fewer than three Business Day prior to the date of the Closing, and (ii) Boston
Scientific shall deliver to Abbott stock certificates evidencing the Shares
having the legend described in Section 6.03.

 

SECTION 6.02.  Sale
Restrictions. (a) Neither Abbott nor any of its Affiliates shall,
directly or indirectly, sell, transfer, assign or otherwise dispose of any
Shares during the six-month period following the Closing; provided that
if the average of the per share closing prices of Shares on the New York Stock
Exchange during any consecutive twenty trading days during the six-month period
following the Closing is greater than $30.00, Abbott may sell Shares in
accordance with Section 6.03 during such six-month period. Neither Abbott
nor any of its Affiliates shall, directly or indirectly, during any one-month
period following the Closing, sell, transfer, assign or otherwise dispose of a
number of Shares that is greater than 8.33% of the Shares acquired by Abbott at
the Closing; provided, however., that such restrictions on the
ability of Abbott or any of its Affiliates to sell, transfer, assign or
otherwise dispose of Shares shall terminate on the date that is eighteen months
following the date of the Closing. The provisions of this Section 6.02(a) may
be amended or waived at any time in accordance with Section 12.07.

 

(b)                                 Nothing in Section 6.02(a) shall
prevent Abbott from selling any of its Shares in any change of control
transaction involving Boston Scientific or from tendering its Shares into any
tender offer for the Shares commenced by Boston Scientific or any other Person.

 

SECTION 6.03.  Registration Rights. (a) For
purposes of this Section 6.03, “Registrable Stock” means the Shares
acquired by Abbott or the applicable Purchaser pursuant to Section 6.01(a) or
6.05 as to which the Registration Statement (as defined in Section 6.03(d))
has not become effective prior to the date of the Closing, and any securities
issued or issuable with respect to such Shares by way of conversion, exchange,
replacement, stock dividend, stock split or other distribution or in connection
with a combination of shares, recapitalization, merger, consolidation or other
reorganization or otherwise. Any Registrable Stock shall cease to be Registrable
Stock when (i) a registration statement covering such Registrable Stock
has been declared effective and such Registrable Stock has been disposed of
pursuant to such effective registration statement, (ii) such Registrable
Stock is sold by a Person in a transaction in which the rights of Abbott under
this Section 6.03 are not assigned, or (iii) such Registrable Stock
is sold pursuant to Rule 144(k) (or any similar provision then in force,
but not Rule 144A) under the Securities Act of 1933, as amended (the “Securities
Act”) without registration under the Securities Act.

 

2

 

(b)                                 Each certificate
representing shares of Registrable Stock shall, except as otherwise provided in
this Section 6.03, be stamped or otherwise imprinted with legends
substantially in the following form:

 

(i)                                    “THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE RESTRICTIONS ON DISPOSITION OF
A TRANSACTION AGREEMENT DATED AS OF
JANUARY 8, 2006, AS AMENDED, BETWEEN
ABBOTT LABORATORIES AND BOSTON SCIENTIFIC CORPORATION.”;
and

 

(ii)                                “THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 AND MAY NOT BE TRANSFERRED OR OTHERWISE DISPOSED OF
UNLESS THEY HAVE BEEN REGISTERED UNDER THAT ACT OR AN EXEMPTION FROM
REGISTRATION IS AVAILABLE.”

 

Each certificate representing Shares acquired by Abbott pursuant to
this Agreement and covered by the Registration Statement shall, except as
otherwise provided in this Section 6.03, be stamped or otherwise imprinted
with a legend substantially in the form set forth in clause (i) of this Section 6.03(b).

 

(c)                                  Boston Scientific
shall, at the request of Abbott, (i) remove from each certificate
evidencing Shares the legend described in Section 6.03(b)(i) at such
time as Abbott and its Affiliates own fewer than 8.33% of the Shares acquired
by Abbott at the Closing, and (ii) remove from each certificate evidencing
Registrable Stock the legend described in Section 6.03(b)(ii) if in
the opinion of counsel satisfactory to Boston Scientific Registrable Stock
evidenced thereby may be publicly sold without registration under the
Securities Act. Boston Scientific shall reasonably cooperate with Abbott to
remove the legends described in Section 6.03(b) so as to allow Abbott
or its Affiliates to sell, transfer, assign or otherwise dispose of Shares as
permitted by Section 6.02.

 

(d)                                 Boston Scientific
shall use its reasonable best efforts to file with, and have declared effective
by, the Securities and Exchange Commission (the “SEC”) on or prior to
the date of the Closing a registration statement on Form S-3 under the
Securities Act (the “Registration Statement”) with respect to the
issuance of the Shares issuable by Boston Scientific to Abbott pursuant to this
Agreement. To the extent such issuance has not been registered pursuant to an
effective Registration Statement on or prior to the date of Closing despite the
use by Boston Scientific of such efforts, Boston Scientific shall, as promptly
as practicable on or following the date of the Closing, file with the SEC a “shelf”
registration statement on Form S-3 pursuant to Rule 415 under the
Securities Act (the “Shelf Registration”) with respect to the Shares
issuable by Boston Scientific to Abbott pursuant to this Agreement, and
thereafter shall use its reasonable best efforts to (i) have the Shelf
Registration declared effective as soon as reasonably practicable thereafter,
and (ii) keep the Shelf Registration continuously effective from the date
such Shelf Registration is declared effective until at least the second
anniversary of such effective date (the “Effectiveness Period”) in order
to permit the prospectus forming a

 

3

 

part thereof to be usable by Abbott and its Affiliates during such
period. Boston Scientific shall use its reasonable best efforts to list the
Shares issuable by Boston Scientific to Abbott pursuant to this Agreement on
the New York Stock Exchange.

 

(e)                                  Notwithstanding anything to the contrary
contained herein, Boston Scientific shall have the right to defer or delay
filing the Shelf Registration for a period of not more than 60 days, or suspend
sales under the Shelf Registration filed hereunder or defer the updating of
such filed Shelf Registration during no more than two periods aggregating not
more than 60 days, in the event that Boston Scientific furnishes to Abbott a
certificate signed by an authorized officer of Boston Scientific stating that,
in the good faith opinion of the Board of Directors of Boston Scientific, such
filing, sale or update would interfere with any material transaction then being
pursued by Boston Scientific or would otherwise require disclosure of any
material event that Boston Scientific would not otherwise be required to
disclose; provided, however, that Boston Scientific shall extend
the Effectiveness Period by the number of days, if any, during with the
registration rights contemplated hereunder are subject to a deferral or
suspension as set forth in this Section 6.03(e).

 

(f)                                    Subject to Section 6.03(e), if Boston
Scientific files a Shelf Registration pursuant to Section 6.03(d), Boston
Scientific shall, as promptly as practicable:

 

(i)                                     supplement or amend the Shelf Registration
and the prospectus used in connection therewith (i) as required by the
registration form utilized by Boston Scientific or by the instructions
applicable to such registration form or by the Securities Act, and (ii) to
include in such Shelf Registration any additional securities that become
Registrable Stock by operation of the definition thereof;

 

(ii)                                  furnish to Abbott such numbers of copies of
the Shelf Registration and the prospectus included therein, including each
preliminary prospectus and any amendments or supplements thereto in conformity
with the requirements of the Securities Act, any exhibits filed therewith and
such other documents and information as Abbott may reasonably request;

 

(iii)                               use all reasonable best efforts to register or qualify the Registrable
Stock covered by the Shelf Registration under such other securities or Blue Sky
Laws of such jurisdiction within the United States as shall be reasonably
appropriate for the distribution of the Registrable Stock covered by the Shelf
Registration; provided, however, that Boston Scientific shall not
be required in connection therewith or as a condition thereto to qualify to do
business in or to file a general consent to service of process in any
jurisdiction wherein it would not but for the requirements of this paragraph
6.03(f)(iii) be obligated to do so; and provided  further,
that Boston Scientific shall not be required to qualify such Registrable Stock
in any jurisdiction in which the securities regulatory authority requires that
Abbott or any of its Affiliates submit any Registrable Stock to the terms,
provisions and restrictions of any escrow, lockup or similar agreement(s) for
consent to sell Registrable Stock in such jurisdiction unless Abbott or such
Affiliate agrees to do so;

 

4

 

(iv)                              promptly notify Abbott upon becoming aware of the happening of any
event as a result of which the prospectus included in such Shelf Registration,
as then in effect, includes an untrue statement of a material fact or omits to
state any material fact required to be stated therein or necessary to make the
statements therein not misleading in light of the circumstances under which
they were made, and, at the request of Abbott, promptly prepare and furnish to
Abbott a reasonable number of copies of a supplement to or an amendment of such
prospectus as may be necessary so that, as thereafter delivered to the
purchasers of such securities, such prospectus shall not include an untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading in
light of the circumstances under which they were made. In the event Boston
Scientific shall give such notice, Boston Scientific shall extend the
Effectiveness Period by the number of days during the period from and including
the date of the giving of such notice to the date when Boston Scientific shall
make available to Abbott such supplemented or amended prospectus; and

 

(v)                                 enter into customary agreements and take such
other actions as are reasonably required in order to expedite or facilitate the
disposition of the Registrable Stock to be so included in the Shelf
Registration.

 

(g)                                 It shall be a condition precedent to the
obligations of Boston Scientific to take any action pursuant to this Section 6.03
that Abbott and its Affiliates shall furnish to Boston Scientific such
information regarding themselves, the Registrable Stock held by them, and the
intended method of disposition of such securities as Boston Scientific shall
reasonably request and as shall be required in connection with the action to be
taken by Boston Scientific hereunder.

 

(h)                                 All expenses incurred in connection with the
Registration Statement and Shelf Registration, if any, excluding underwriters’
discounts and commissions, but including all registration, filing and
qualification fees, word processing, duplicating, printers’ and accounting
fees, listing fees, messenger and delivery expenses, all fees and expenses of
complying with state securities or blue sky laws, and the fees and
disbursements of counsel for Boston Scientific, shall be paid by Boston
Scientific. Abbott shall bear and pay the underwriting commissions and
discounts applicable to Registrable Stock offered for its account and the fees
and disbursements of its counsel in connection with any registrations, filings
and qualifications made pursuant to this Agreement.

 

(i)                                     Boston Scientific shall indemnify and hold
harmless Abbott and its Affiliates, officers and directors against any losses,
claims, damages or liabilities, joint or several, to which they may become
subject under the Securities Act or otherwise, insofar as such losses, claims,
damages or liabilities (or proceedings in respect thereof) arise out of or are
based on any untrue or alleged untrue statement of any material fact contained
in the Registration Statement or the Shelf Registration, as applicable, on the
effective date thereof (including any prospectus filed under Rule 424
under the Securities Act, or any amendments or supplements thereto) or arise
out of or are based upon the omission or

 

5

 

alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and shall reimburse
Abbott and its Affiliates, officers and directors for any legal or other
expenses reasonably incurred by them (but not in excess of expenses incurred in
respect of one counsel for all of them) in connection with investigating or
defending any such loss, claim, damage, liability or action; provided, however,
that the indemnity agreement contained in this Section 6.03(i) shall
not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of
Boston Scientific (which consent shall not be unreasonably withheld); provided,
further, that Boston Scientific shall not be liable to Abbott or its
Affiliates, officers or directors in any such case for any such loss, claim,
damage, liability or action to the extent that it arises out of or is based
upon an untrue statement or alleged untrue statement or omission or alleged
omission made in connection with such Registration Statement, Shelf
Registration, preliminary prospectus, final prospectus or amendments or
supplements thereto, in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by
Abbott or any of its Affiliates, officers or directors. Such indemnity shall
remain in full force and effect regardless of any investigation made by or on
behalf of Abbott or any of its Affiliates, officers or directors.

 

(j)                                     Abbott shall indemnify and hold harmless
Boston Scientific, its Affiliates, officers and directors and each agent and
any underwriter for Boston Scientific (within the meaning of the Securities
Act) against any losses, claims, damages or liabilities, joint or several, to
which Boston Scientific or any such Affiliate, officer, director, agent or
underwriter may become subject, under the Securities Act or otherwise, insofar
as such losses, claims, damages or liabilities (or proceedings in respect
thereof) arise out of or are based upon any untrue statement or alleged untrue
statement of any material fact contained in the Registration Statement or Shelf
Registration, as applicable, on the effective date thereof (including any
prospectus filed under Rule 424 under the Securities Act or any amendments
or supplements thereto) or arise out of or are based upon the omission or
alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading, in each case to the
extent that such untrue statement or alleged untrue statement or omission or
alleged omission was made in such Registration Statement, Shelf Registration,
preliminary or final prospectus, or amendments or supplements thereto, in
reliance upon and in conformity with written information furnished by or on
behalf of Abbott or any of its Affiliates expressly for use in connection with
such registration; and Abbott shall reimburse any legal or other expenses
reasonably incurred by Boston Scientific or any such Affiliate, officer,
director, agent or underwriter in connection with investigating or defending
any such loss, claim, damage, liability or action; provided, however,
that the indemnity agreement contained in this Section 6.03(j) shall not
apply to amounts paid in settlement of any such loss, claim, damage, liability
or action if such settlement is effected without the consent of Abbott (which
consent shall not be unreasonably withheld). Such indemnity shall remain in
full force and effect regardless of any investigation made by or on behalf of
Boston Scientific or any of its Affiliates, officers or directors.

 

6

 

(k)                                  Promptly after receipt by an indemnified
party under Section 6.03(i) or (j), as applicable, of notice of the
commencement of any action, such indemnified party shall, if a claim in respect
thereof is to be made against any indemnifying party under Section 6.03(i) or
(j), as applicable, notify the indemnifying party in writing of the
commencement thereof, and the indemnifying party shall have the right to
participate in and assume the defense thereof with counsel selected by the
indemnifying party and reasonably satisfactory to the indemnified party (unless
(i) such indemnified party reasonably objects to such assumption on the
grounds that there may be defenses available to it which are different from or
in addition to those available to such indemnifying party, (ii) the
indemnifying party and such indemnified party shall have mutually agreed to the
retention of such counsel or (iii) in the reasonable opinion of such
indemnified party, representation of such indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or
potential differing interests between such indemnified party and any other
party represented by such counsel in such proceeding, in which case the
indemnified party shall be reimbursed by the indemnifying party for the
reasonable expenses incurred in connection with retaining separate legal
counsel); provided, however, that an indemnified party shall have
the right to retain its own counsel, with all fees and expenses thereof to be
paid by such indemnified party, and to be apprised of all progress in any
proceeding the defense of which has been assumed by the indemnifying party, it
being understood that the indemnifying party will control such defense. The
failure to notify an indemnifying party promptly of the commencement of any
such action shall not relieve the indemnifying party from any liability in
respect of such action which it may have to such indemnified party on account
of the indemnity contained in Section 6.03(i) or (j), as applicable,
unless (and only to the extent) the indemnifying party was prejudiced by such
failure, and in no event shall such failure relieve the indemnifying party from
any other liability which it may have to such indemnified party. No
indemnifying party shall, without the prior written consent of the indemnified
party (which consent will not be unreasonably withheld), effect any settlement,
compromise or discharge of any claim or pending or threatened proceeding in respect
of which the indemnified party is or could have been a party and indemnity
could have been sought hereunder by such indemnified party, unless such
settlement, compromise or discharge includes an unconditional release of such
indemnified party from all liability arising out of such claim or proceeding.

 

(l)                                     To the extent any indemnification by an
indemnifying party is prohibited or limited by Law, the indemnifying party, in
lieu of indemnifying such indemnified party, shall contribute to the amount paid
or payable by such indemnified party as a result of such losses, claims,
damages or liabilities in such proportion as is appropriate to reflect the
relative fault of the indemnifying party and indemnified party in connection
with the actions which resulted in such losses, claims, damages or liabilities,
as well as any other relevant equitable considerations. The relative fault of
such indemnifying party and indemnified party shall be determined by reference
to, among other things, whether any action in question, including any untrue or
alleged untrue statement of material fact or omission or alleged omission to
state a material fact, has been made by, or relates to information supplied by,
such indemnifying party or indemnified party, and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent

 

7

 

such
action. The amount paid or payable by a party as a result of the losses,
claims, damages or liabilities referred to above shall be deemed to include any
legal or other fees or expenses reasonably incurred by such party in connection
with any investigation or proceeding. In no event shall the liability of any
indemnifying party be greater in amount than the amount for which such
indemnifying party would have been obligated to pay by way of indemnification
if the indemnification provided for under Section 6.03(i) or (j)
hereof had been available under the circumstances. The parties hereto agree
that it would not be just and equitable if contribution pursuant to this Section 6.03(l) were
determined by pro rata allocation or by any other method of allocation which
does not take account of the equitable considerations referred to in this Section 6.03(l).
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation.

 

SECTION 6.04.  Loan
Prepayment. If, at any time during the term of the loan described in Section 5.10,
Abbott or any of its Affiliates sells any Shares, then Abbott and Boston
Scientific shall share in the proceeds per share (net of any underwriting
discounts and commissions) (the “Net Proceeds”) as follows: (a) if
the Net Proceeds to Abbott or such Affiliates from any such sales are less than
or equal to 110% of the Stock Purchase Price, Abbott shall retain all of such
Net Proceeds, (b) if the Net Proceeds to Abbott or such Affiliates from
any such sales are greater than 110% but equal to or less than 120% of the
Stock Purchase Price, Abbott shall retain the portion of the Net Proceeds equal
to 110% of the Stock Purchase Price, and the portion of the Net Proceeds in
excess of 110% of the Stock Purchase Price (net of Taxes) shall be immediately
applied by Abbott to prepay any amounts then outstanding under the loan in
accordance with Section 5.10(b), and (c) if the Net Proceeds to
Abbott or such Affiliates from any such sales are greater than 120% of the
Stock Purchase Price, Abbott shall retain the portion of the Net Proceeds equal
to 110% of the Stock Purchase Price, the portion of the Net Proceeds in excess
of 110% but less than or equal to 120% of the Stock Purchase Price (net of
Taxes) shall be immediately applied by Abbott to prepay any amounts then
outstanding under the loan in accordance with Section 5.10(b), and, with
respect to all Net Proceeds in excess of 120% of the Stock Purchase Price, 50%
of such excess amount shall be retained by Abbott, and the remaining 50% (net
of Taxes) shall be immediately applied by Abbott to prepay any amounts then
outstanding under the loan in accordance with Section 5.10(b). Abbott
shall notify Boston Scientific in writing within three Business Days of any
such sales of Shares by it or any of its Affiliates, and shall include in such
notice the number of Shares sold by it or such Affiliates, the selling price
for such Shares, and the amount of Taxes payable by Abbott or such Affiliates
with respect to such sales, and shall give a third party designated by Boston
Scientific and reasonably acceptable to Abbott reasonable access to the books
and records of Abbott for purposes of verifying such information.

 

SECTION 6.05.  Interest
Reimbursement. On the date that is eighteen months following the Closing
Date, Boston Scientific shall issue to Abbott a number of Shares that is equal
to the quotient obtained by dividing the Cost of Borrowing (as defined below)
by the average of the per share closing prices of Shares on the New York Stock

 

8

 

Exchange during the twenty consecutive trading days ending (and
including) the date that is five trading days prior to such date. For purposes
of this Section 6.05, the “Cost of Borrowing” means Abbott’s actual
cost of borrowing incurred during the period commencing on the date of the
Closing and ending on the eighteen month anniversary of the Closing of the
funds used by it or the applicable Purchaser to pay the Aggregate Stock
Purchase Price; provided that Boston Scientific will only be required to
reimburse Abbott pursuant to this Section 6.05 with respect to any Cost of
Borrowing greater than $10 million and less than or equal to $70 million; provided
further that, for purposes of calculating the Cost of Borrowing, the Net
Proceeds to Abbott or any of its Affiliates from sales of Shares that are
retained by Abbott as described in Section 6.04 shall be deemed to have
been applied by Abbott (net of Taxes) to reduce the amount of Abbott’s
borrowing in respect of the Aggregate Stock Purchase Price. Nothing contained
in this Section 6.05 shall require Abbott to make any actual payment with
respect to such borrowing. Abbott shall notify Boston Scientific in writing on
a quarterly basis following the Closing of its Cost of Borrowing during the
immediately preceding quarter, which Cost of Borrowing shall be subject to
audit by a third party designated by Boston Scientific and reasonably
acceptable to Abbott. Any Shares issued by Boston Scientific pursuant to this Section 6.05
shall bear the legend described in Section 6.03(b)(ii), which shall be
removed at the request of Abbott in accordance with Section 6.03(c)(ii).”

 

SECTION 2.  Public Announcement. The provisions
contained in Section 12.03 of the Agreement are incorporated by reference
in this Amendment as though they were expressly set forth herein.

 

SECTION 3.
 Representations and Warranties. (a) Boston
Scientific represents and warrants to Abbott as follows:

 

(i)                                     Boston Scientific is a corporation duly
incorporated, validly existing and in good standing under the Laws of the State
of Delaware and has all necessary corporate power and authority to enter into,
execute and deliver this Amendment, to carry out its obligations hereunder and
to consummate the transactions contemplated hereby. The execution and delivery
of this Amendment by Boston Scientific, the performance by Boston Scientific of
its obligations hereunder and the consummation by Boston Scientific of the
transactions contemplated hereby have been duly authorized by all requisite
corporate action on the part of Boston Scientific. This Amendment has been duly
executed and delivered by Boston Scientific, and, assuming due authorization,
execution and delivery by Abbott, this Amendment is a legal, valid and binding
obligation of Boston Scientific, enforceable against it in accordance with its
terms.

 

(ii)                                  All Shares issued pursuant to Sections 6.01
and 6.05 shall, when issued, be validly issued, fully paid and nonassessable,
and shall be free and clear of any liens, claims, charges and encumbrances
other than those imposed as a result of any action by Abbott or any of its
Affiliates.

 

(b)                                 Abbott represents and warrants to Boston
Scientific as follows: Abbott is a corporation duly incorporated, validly
existing and in good standing under the laws of the State

 

9

 

of Illinois and has all
necessary corporate power and authority to enter into, execute and deliver this
Amendment, to carry out its obligations hereunder and to consummate the
transactions contemplated hereby. The execution and delivery of this Amendment
by Abbott, the performance by Abbott of its obligations hereunder and the
consummation by Abbott of the transactions contemplated hereby have been duly authorized
by all requisite corporate action on the part of Abbott. This Amendment has
been duly executed and delivered by Abbott, and, assuming due authorization,
execution and delivery by Boston Scientific, this Amendment is a legal, valid
and binding obligation of Abbott enforceable against it in accordance with its
terms.

 

SECTION 4.  Ratification of Agreement. Except as
expressly provided in this Amendment, all of the terms, covenants, and other
provisions of the Agreement are hereby ratified and confirmed and shall
continue to be in full force and effect in accordance with their respective
terms. From and after the date hereof, all references to the Agreement shall
refer to the Agreement as amended by this Amendment. Capitalized terms used but
not defined in this Amendment shall have the meanings assigned to them in the
Agreement.

 

SECTION 5.  Governing Law. This Amendment shall be
governed by, and construed in accordance with, the laws of the State of New
York. All Actions arising out of or relating to this Amendment shall be heard
and determined exclusively in any New York federal court sitting in the Borough
of Manhattan of The City of New York.

 

SECTION 6.  Counterparts. This Amendment may be
executed and delivered (including by facsimile transmission) in one or more
counterparts, and by the different parties hereto in separate counterparts,
each of which when executed shall be deemed to be an original, but all of which
taken together shall constitute one and the same agreement.

 

* 
*  *  *

 

10

 

IN WITNESS WHEREOF, Boston Scientific and Abbott have caused this Amendment
to be executed as of the date first written above by their respective officers
thereunto duly authorized.

 

	
   

  	
  BOSTON
  SCIENTIFIC CORPORATION

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Lawrence
  C. Best

  	
   

  
	
   

  	
  Name:

  	
  Lawrence C.
  Best

  
	
   

  	
  Title:

  	
  Executive
  Vice President, Chief

  Financial Officer

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  ABBOTT
  LABORATORIES

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Richard
  A. Gonzalez

  	
   

  
	
   

  	
  Name:

  	
  Richard A.
  Gonzalez

  
	
   

  	
  Title:

  	
  President
  and Chief Operating

  Officer, Medical Products

  Group

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]